K5 Therapeutics SRL
17.8 FTEK5 Therapeutics reported total assets of €3.56m at the end of the 2025 financial year (annual accounts filed with the NBB on 11 Jun 2026), with 17.8 full-time equivalents.
The score of K5 Therapeutics shows with a free account.
See the score- Summary? / 5
- Balance sheet strength
- Liquidity
- Repayment capacity
- Profitability
- Trajectory
- Compliance and register
- Position in its sectorvs peers
- Supplier creditat 30 d
- Borrowing capacityborrowable
- Valuationcentral
Visible once signed in: create your account, the 14-day Pro trial is free.
Key figures 2025
Change 2022 → 2025: Equity +24 % Total assets +22 % Headcount (avg FTE) +559 %
Accounts of the company itself (not consolidated).
The full file covers 5 financial years; a free account shows 2. →Deterministic calculation on the filed accounts, no AI. Dispute the score or report an error
K5 Therapeutics's annual accounts
Filed annual accounts
- Year ended 31 Dec 2025filed on 11 Jun 2026
- Year ended 31 Dec 2024filed on 24 Jun 2025
- Year ended 31 Dec 2023filed on 26 Jun 2024
- Year ended 31 Dec 2022filed on 07 Jul 2023
- Year ended 31 Dec 2021filed on 28 Jul 2022
K5 Therapeutics's financial analysis
- Solvency83.1%sector median: 60.4%
- Current ratio
- Net margin
- ROE
- Financial debt / EBITDA
- Interest coverage
- Days sales outstanding (DSO)
Management and control of K5 Therapeutics
K5 Therapeutics's publications in the Belgian Gazette
Company number, VAT number and registered office
- Company number (CBE)
- 0757.718.072
- VAT number
- BE0757718072
- Peppol
- Registered · 0208:0757718072 · as of 10 Nov 2026
- Legal form
- SRL
- Incorporated
- 02 Nov 2020
- Registered office
- 3001 Leuven
- Size
- Small · 17.8 FTE
- Latest accounts
- 2025 · filed on 11 Jun 2026
- Activity
- Research and experimental development on biotechnology (NACE 72101)
K5 Therapeutics (SRL) has been based in Leuven since 2020, active in: research and experimental development on biotechnology. For 2025, it reports a net profit of 261,735 € and equity of €2.96m; its revenue is not published. With 17.8 full-time equivalents, it is a small enterprise by headcount. Its solvency stands at 83.1%, above the median of its sector (60.4%).
Guide: Reading Belgian SME accounts: the five figures that count →
Companies similar to K5 Therapeutics
Companies in the same business, of comparable size and area, outside its group.
- NanoBiotech Research and experimental development on natural sciences and engineering Diepenbeek · balance sheet 1,834 €
- ImmuneSpec Research and experimental development on natural sciences and engineering Niel · balance sheet €3.54m
- Envitec Measurements and Analytics SA Research and experimental development on natural sciences and engineering Gembloux · balance sheet €3.64m
- HepaVue Dx Research and experimental development on natural sciences and engineering Waterloo · balance sheet €3.71m
- Dr. J. Bellon Research and experimental development on natural sciences and engineering Buggenhout · balance sheet €3.14m
- Elmace Research and experimental development on natural sciences and engineering Aalter · balance sheet €3.11m
- Pacira Belgium Research and experimental development on natural sciences and engineering Eupen · balance sheet €3.00m
- Montis Biosciences Research and experimental development on natural sciences and engineering Leuven · balance sheet €2.97m
Frequently asked questions about K5 Therapeutics
What is the revenue of K5 Therapeutics?
K5 Therapeutics files its accounts in a format where revenue is optional: it is not published for 2025.
What is the VAT number of K5 Therapeutics?
In Belgium, the VAT number is the company number prefixed with BE: BE0757718072 for K5 Therapeutics, if the company is VAT-registered. Its company number (CBE) is 0757.718.072.
Where is the registered office of K5 Therapeutics?
According to the CBE register, the registered office of K5 Therapeutics is in 3001 Leuven.
What is the equity of K5 Therapeutics?
At the close of the 2025 financial year, the equity of K5 Therapeutics amounts to 2,959,218 €, a solvency of 83.1% of total assets.
How many people work at K5 Therapeutics?
17.8 full-time equivalents on average according to the 2025 social balance sheet.
Who manages K5 Therapeutics?
The register lists 3 active mandates at K5 Therapeutics. Names and roles are in the full file, with the deeds published in the Belgian Gazette.
The full file of K5 Therapeutics
Directors and mandates, ownership network, Gazette deeds, ten years of accounts and ratios, Excel export, and Idonis's analysis in one question.
Open the full file →